


Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. – 8. (Cancelled).

9. (New) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R¹ represents branched C₃₋₆ alkyl, C₃₋₅ cycloalkyl or -C₁₋₄ alkylC₃₋₄ cycloalkyl;

R² represents halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, cyano, amino or trifluoromethyl;

n represents 0, 1 or 2;

R³ represents -X-aryl, -X-heteroaryl, -X-heterocyclyl, -X-aryl-aryl, -X-aryl-heteroaryl, -X-aryl-heterocyclyl, -X-heteroaryl-aryl, -X-heteroaryl-heteroaryl, -X-heteroaryl-heterocyclyl, -X-heterocyclyl-aryl, -X-heterocyclyl-heteroaryl or -X-heterocyclyl-heterocyclyl;

such that when R³ represents -X-piperidinyl, -X-piperidinyl-aryl, -X-piperidinyl-heteroaryl or -X-piperidinyl-heterocyclyl said piperidinyl group is attached to X via a nitrogen atom;

wherein R³ is attached to the phenyl group of formula (I) at the 3 or 4 position;

X represents a bond, O, CO, SO₂, CH₂O, OCH₂, NR⁴, NR⁴CO or C₁₋₆ alkyl;

R⁴ represents hydrogen or C₁₋₆ alkyl;

wherein said aryl, heteroaryl or heterocyclyl groups of R³ may be optionally substituted by one or more halogen, hydroxy, cyano, nitro, oxo, haloC₁₋₆ alkyl, haloC₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, arylC₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxyC₁₋₆ alkyl, C₃₋₇ cycloalkylC₁₋₆ alkoxy, C₃₋₇ cycloalkylcarbonyl, -COC₁₋₆

alkyl, C₁₋₆ alkoxy carbonyl, arylC₁₋₆ alkyl, heteroarylC₁₋₆ alkyl, heterocyclylC₁₋₆ alkyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyloxy, C₁₋₆ alkylsulfonylC₁₋₆ alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC₁₋₆ alkyl, aryloxy, -CO-aryl, -CO-heterocyclyl, -CO-heteroaryl, C₁₋₆ alkylsulfonamidoC₁₋₆ alkyl, C₁₋₆ alkylamidoC₁₋₆ alkyl, arylsulfonamido, arylaminosulfonyl, arylsulfonamidoC₁₋₆ alkyl, arylcarboxamidoC₁₋₆ alkyl, aroylC₁₋₆ alkyl, arylC₁₋₆ alkanoyl, or a group NR¹⁵R¹⁶, -NR¹⁵CO-aryl, -NR¹⁵CO-heterocyclyl, -NR¹⁵CO-heteroaryl, -CONR¹⁵R¹⁶, -NR¹⁵COR¹⁶, -NR¹⁵SO₂R¹⁶ or -SO₂NR¹⁵R¹⁶ groups, wherein R¹⁵ and R¹⁶ independently represent hydrogen or C₁₋₆ alkyl; or solvates thereof.

10. (New) A compound according to claim 9 which is:

4'-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]-4-biphenylcarbonitrile;

1-{4'-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]-4-biphenyl}ethanone;

1-(4-Biphenylcarbonyl)-4-cyclobutylhexahydro-1*H*-1,4-diazepine;

{4-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl}(phenyl)methanone;

1-Cyclobutyl-4-{[4-(phenyloxy)phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;

1-Cyclobutyl-4-{[4-[(phenylmethyl)oxy]phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;

1-Cyclobutyl-4-{[4-tetrazol-1-yl]phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;

1-Cyclobutyl-4-{[4-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;

1-Cyclobutyl-4-{[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;

1-(Isopropyl)-4-{[4-(tetrahydro-2*H*-pyran-4-yloxy)phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;

1-Cyclobutyl-4-{[4-[6-(trifluoromethyl)-3-pyridinyl]phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;

6-{4-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl}-3-cyanopyridine;

5-{4-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl}-*N*-methyl-2-pyridinecarboxamide;

5-{4-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl}-2-cyanopyridine;

5-(4-{[4-(1-Isopropyl)hexahydro-1*H*-1,4-diazepin-1-yl]carbonyl}phenyl)-2-cyanopyridine;

N-Methyl-5-(4-{[4-(1-isopropyl)hexahydro-1*H*-1,4-diazepin-1-yl]carbonyl}phenyl)-2-pyridinecarboxamide;

1-(1-Methylethyl)-4-({4-[2-(trifluoromethyl)-5-pyrimidinyl]phenyl}carbonyl)hexahydro-1*H*-1,4-diazepine;

1-(1-Methylethyl)-4-({4-[6-(trifluoromethyl)-3-pyridazinyl]phenyl}carbonyl)hexahydro-1*H*-1,4-diazepine;

1-(1-Methylethyl)-4-({4-[6-(trifluoromethyl)-3-pyridinyl]phenyl}carbonyl)hexahydro-1*H*-1,4-diazepine;

N,N-Dimethyl-5-(4-{[4-(1-methylethyl)hexahydro-1*H*-1,4-diazepin-1-yl]carbonyl}phenyl)-2-pyridinecarboxamide;

6-(4-{[4-(1-Methylethyl)hexahydro-1*H*-1,4-diazepin-1-yl]carbonyl}phenyl)-3-pyridinecarbonitrile;

1-Cyclobutyl-4-({4-[6-(trifluoromethyl)-3-pyridazinyl]phenyl}carbonyl)hexahydro-1*H*-1,4-diazepine;

1-Cyclobutyl-4-({4-[2-(trifluoromethyl)-5-pyrimidinyl]phenyl}carbonyl)hexahydro-1*H*-1,4-diazepine;

4'-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]-3-biphenylcarboxamide;

1-{4-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl}-3-(trifluoromethyl)-1*H*-pyrazole-4-carbonitrile;

1-({4-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl)methyl)-5-(trifluoromethyl)-2(1*H*)-pyridinone;

4'-{[4-(1-Methylethyl)hexahydro-1*H*-1,4-diazepin-1-yl]carbonyl}-4-biphenylcarbonitrile;

N-{4-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl}-*N*,4,6-trimethyl-2-pyrimidinamine;

1-Cyclobutyl-4-[(3'-fluoro-4-biphenyl)carbonyl]hexahydro-1*H*-1,4-diazepine;

1-Cyclobutyl-4-{{4-(2-pyridinyl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;
1-Cyclobutyl-4-{{4-(3-pyridinyl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;
4-{{4-{{4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl}carbonyl}phenyl}oxy)benzonitrile;
1-Cyclobutyl-4-{{4-{{(phenyloxy)methyl}phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;
1-Cyclobutyl-4-{{4-(3,5-dimethyl-4-isoxazolyl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;
1-{{4-(3,5-Dimethyl-4-isoxazolyl)phenyl}carbonyl}-4-(1-methylethyl)hexahydro-1*H*-1,4-diazepine;
1-Cyclobutyl-4-{{4-(1,3-oxazol-5-yl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;
1-Cyclobutyl-4-{{4-(2-ethyl-2*H*-tetrazol-5-yl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;
1-Cyclobutyl-4-{{4-(1*H*-pyrrol-1-yl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;
1-Cyclobutyl-4-{{4-(3,5-dimethyl-1*H*-pyrazol-1-yl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;
1-Cyclobutyl-4-{{4-{{(3,5-dimethyl-1*H*-pyrazol-1-yl)methyl}phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;
1-Cyclobutyl-4-{{4-(4-morpholinyl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;
1-(1-Methylethyl)-4-{{4-(4-morpholinyl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine hydrochloride
1-Cyclobutyl-4-{{3-{{(phenyloxy)methyl}phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;
1-Cyclobutyl-4-{{3-{{(3-pyridinylmethyl)oxy}phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;
1-Cyclobutyl-4-{{3-{{(3-pyridinylmethyl)oxy}phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;
1-Cyclobutyl-4-{{3-(5-methyl-1*H*-tetrazol-1-yl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;
1-{{3-{{4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl}carbonyl}phenyl}-2-pyrrolidinone;

N-{3-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl}-3-pyridinecarboxamide;
N-{3-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl}-4-pyridinecarboxamide;
1-Cyclobutyl-4-{[3-(3-pyridinyl)phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;
1-Cyclobutyl-4-{[4'-(1,3-oxazol-2-yl)-4-biphenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;
1-Cyclobutyl-4-{[4'-(2-methyl-1,3-oxazol-4-yl)-4-biphenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;
1-Cyclobutyl-4-{[4'-(2-methyl-1,3-oxazol-5-yl)-4-biphenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;
1-Cyclobutyl-4-{[4'-(5-methyl-1,2,4-oxadiazol-3-yl)-4-biphenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;
1-Cyclobutyl-4-{[4-(1,3-oxazol-2-yl)phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;
1-(1-Methylethyl)-4-{[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;
1-Cyclobutyl-4-{[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;
or a pharmaceutically acceptable salt or solvate thereof.

11. (New) A pharmaceutical composition which comprises the compound of formula (I) as defined in claim 9 or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier or excipient.

12. (New) A method of treatment of neurological diseases which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in claim 9 or a pharmaceutically acceptable salt or solvate thereof.